October DCI Seminar Series

October 23, 2019
8:00am to 9:00am

The guest speaker for the October DCI Seminar Series is Qing Yi, MD, PhD, associate director of  Houston Methodist Cancer Center and director of the Houston Methodist Center for Translational Research in Hematologic Malignancies since September 2018. Yi will present on “Developmental therapeutics for multiple myeloma.”

Previous to his current position, Yi was chair of the Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic (May 2013 to Aug. 2018), and before that, a professor of medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston. 

Yi is a trained medical immunologist and one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers. His lab's most recent research focuses on developing novel therapeutic monoclonal antibodies for myeloma and other cancers; identifying T-cell subsets that have potent anti-tumor effects after adoptive transfer; and identifying tumor micro-environment components that induce tumor drug resistance.

Yi earned his MD at Sun Yat Sen University of Medical Sciences, Guangzhou, China, and his PhD at Karolinska Institutet, Stockholm, Sweden.

Since arriving in the US in 1998, Yi's been awarded, as the PI, nine R01s from the National Cancer Institute; one project and one core grant in the MDACC Myeloma SPORE (P50); four R01-type translational grants from the Leukemia & Lymphoma Society; two K99/R00 grants (as the mentor), and numerous other grants. His current research is supported by four grants from the NCI and a grant from the Cancer Prevention & Research Institute of Texas.

The October DCI Seminar Series is presented by the DCI Hematologic Malignancies and Cellular Therapies Program and is held in conjunction with Hematology Oncology Grand Rounds.

Print poster for distribution.

Location

Trent Semans Center, Great Hall.

Contact

For more information, contact Erin Carr.